Successful and cost-effective thromboprophylaxis requires the accurate identification of thromboembolic risk in different patient groups, and the use of appropriate prophylactic measures.
Although numerous factors are known to affect risk levels, to date no evidence-based risk assessment model (RAM) has been devised that has been widely adopted by clinicians to assist in making decisions about the use of physical and pharmacological thromboprophylactic methods in different patients.
Recent consensus documents have been published which attempt to address this important issue, using epidemiological and other evidence to define risk levels and support therapy recommendations.
This session will provide an overview of the backgrounds to several of these documents, and summarize their recommendations.